Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections-Reference-Cited by-同舟云学术

Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections

Published:2023-04-18 Issue:4 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Negatu Dereje A.¹²^ORCID,Aragaw Wassihun Wedajo¹,Cangialosi Julianna¹,Dartois Véronique¹³^ORCID,Dick Thomas¹³⁴^ORCID

Affiliation:

1. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA

2. Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia

3. Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA

4. Department of Microbiology and Immunology, Georgetown University, Washington, DC, USA

Abstract

New oxazolidinones are in clinical development for the treatment of tuberculosis and nontuberculous mycobacterial (NTM) infections, as a replacement for linezolid and tedizolid, which cause mitochondrial toxicity after prolonged treatment. Here, we carried out side-by-side measurements of mitochondrial protein synthesis inhibition and activity against clinically relevant mycobacterial pathogens of approved and novel oxazolidinones.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01655-22

Reference41 articles.

1. World Health Organization. 2022. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.

2. Linezolid for Drug-Resistant Tuberculosis

3. Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments

4. Tedizolid vs Linezolid for the Treatment of Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients

5. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in pulmonary drug‐resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-01-25

2. Case report: Successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid;Frontiers in Medicine;2023-10-19

3. Characterization of In Vitro Resistance to Linezolid in Mycobacterium abscessus;Microbiology Spectrum;2023-08-17